|

HC-7366 Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Pipeline

Phase 1: 3

Top Sponsors

  • M.D. Anderson Cancer Center2
  • HiberCell, Inc.1

Indications

  • Cancer3
  • SHARK1
  • HC-73661
  • Phase 1b1
  • Kidney Cancer1

Houston, Texas2 trials

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

MD Anderson Cancer Center

Phase 1
Phase I Study of HC-7366 for Acute Myeloid Leukemia

MD Anderson Cancer Center

Phase 1

Tucson, Arizona1 trial

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

University of Arizona Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.